pembrolizumab
merck
['melsm', 'melanoma', 'pembro']
#asco23: keynote-726 update: in pts w/ stage iib/iic #melanoma, adjuvant pembro provides a 41% reduction in the risk of distant metastasis or death &amp; a 38% reduction in the risk of recurrence or death: #immunotherapy #melsm 
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ≠ endorse.